Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer - Abstract

Biphosphonates have long been the standard of care for antiresorptive treatment of bone metastases from castrate-resistant prostate cancer (mCRPC).

Although the indication has historically been mostly palliative, response rates in skeletal-related events (SRE) remain low. Denosumab has been shown to be effective in prolonging time to first SRE in clinical settings, however, critical questions remain on its ability to affect bone metastases in mCRPC. The landscape for research progress in reducing SREs using novel pharmacotherapies is growing rapidly, with several agents in clinical trials. This focused review outlines the most promising investigational drugs for treating bone metastases in mCRPC.

Written by:
Spencer S, Marini BL, Figg WD.   Are you the author?
Pharm.D., Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bldg 10/Room 5A01, 9000 Rockville Pike, Bethesda, MD 20892, U.S.A.

Reference: Anticancer Res. 2012 Jul;32(7):2391-8.

PubMed Abstract
PMID: 22753695 Prostate Cancer Section